• Glutamine for the Treatment of Patients With Irritable Bowel Syndrome

  NCT01414244

  CompletedInterventionalPhase 2Updated Aug 9, 2017
• Effectiveness of a Dietary Supplement in Irritable Bowel Syndrome

  NCT07039747

  RecruitingInterventionalPhase 2Updated Feb 23, 2026
• A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia

  NCT05655819

  CompletedInterventionalPhase 1Phase 2Updated Feb 3, 2026
• Effect of Glutamine on Intestinal Permeability in Crohn's Disease

  NCT00838149

  CompletedInterventionalPhase 1Updated Feb 6, 2009
• Effects of Oral Glutamine Supplementation on Insulin Resistance and Functional Intestinal Disorders in Obese Patients.

  NCT04883515

  RecruitingInterventionalNot ApplicableUpdated Feb 6, 2026
• Enteral Versus Parenteral Glutamine Supplement

  NCT00875797

  TerminatedInterventionalPhase 4Updated Jan 16, 2014

ClinicalTrials.gov ID

NCT06291038

Lead Sponsor

University Hospital, RouenOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

60Estimated

Last Update Posted

Feb 20, 2026Actual

Start Date

Oct 3, 2024Actual

Primary Completion Date

Mar 1, 2029Estimated

Completion Date

Mar 1, 2029Estimated

Official Title

Efficacy of Glutamine Supplementation in Patients Suffering From Irritable Bowel

Brief Summary

Irritable bowel syndrome (IBS) affects approximately 5% of the general population and remains a daily problem in the practice of clinicians with inconsistent effectiveness of treatments while patients' expectations are high.

One of the functional abnormalities described during IBS is increased intestinal permeability. This increase in intestinal permeability is primarily present in the diarrheal subtype (IBS-D) and can be measured using the lactulose/mannitol test.

Glutamine is a non-essential amino acid which regulates numerous metabolic pathways, and which plays a key role in the intestine because it is the preferential substrate of enterocytes and immune cells. Ex vivo, glutamine is able to restore the expression of tight junction proteins in patients suffering from IBS-D. On the other hand, glutamine supplementation is capable of reducing abdominal pain and restoring intestinal permeability disorders in a subgroup of patients with intestinal permeability disorder (post-infectious IBS-D).

The working hypothesis would be that all patients suffering from IBS with permeability disorder, measured by the lactulose/mannitol test, could benefit from oral glutamine supplementation.

Detailed Description

Irritable bowel syndrome (IBS) affects approximately 5% of the general population and remains a daily problem in the practice of clinicians with inconsistent effectiveness of treatments while patients' expectations are high.

One of the functional abnormalities described during IBS is increased intestinal permeability. This increase in intestinal permeability is primarily present in the diarrheal subtype (IBS-D) and can be measured using the lactulose/mannitol test.

Glutamine is a non-essential amino acid which regulates numerous metabolic pathways, and which plays a key role in the intestine because it is the preferential substrate of enterocytes and immune cells. Ex vivo, glutamine is able to restore the expression of tight junction proteins in patients suffering from IBS-D. On the other hand, glutamine supplementation is capable of reducing abdominal pain and restoring intestinal permeability disorders in a subgroup of patients with intestinal permeability disorder (post-infectious IBS-D).

The working hypothesis would be that all patients suffering from IBS with permeability disorder, measured by the lactulose/mannitol test, could benefit from oral glutamine supplementation.

• Irritable Bowel Syndrome

• • Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks
• • Control group: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Adult aged 18 to 75
• Diarrheal irritable bowel syndrome (IBS-D), according to the Rome IV criteria (appendix 2)
• Francis score > 175/500 at inclusion (corresponding to moderate to severe IBS)
• Treatments for IBS stable for >1 month
• Affiliation to a social security system
• Adult person having read and understood the information letter and signed the consent form
• Woman of childbearing age having effective/very effective contraception (Cf. CTFG) (estrogen-progestins or intrauterine device or tubal ligation) for 1 month and a negative urine pregnancy test
• Postmenopausal woman: confirmatory diagnosis (amenorrhea not medically induced for at least 12 months before the inclusion visit or biologically documented)

Exclusion Criteria:

• Taking probiotics, anti-inflammatories, corticosteroids or antibiotics systemically (oral or injectable) in the month preceding the study and during the duration of the study treatment,
• Known diagnosis of active autoimmune disease (type 1 diabetes, lupus, multiple sclerosis, thyroiditis, ankylosing spondylitis, rheumatoid arthritis or psoriasis)
• Known allergy to glutamine,
• Contraindication to taking glutamine, protein powder, lactulose or mannitol (including sugar-free chewing gum),
• Use of osmotic laxatives and/or taking lactulose and/or protein supplementation (including taking glutamine) in the 4 weeks preceding the start of the study,
• Renal insufficiency (GFR<40mL/min), hepatic insufficiency (PT<70) or known heart disease,
• ATCD of digestive disease (celiac disease, chronic inflammatory bowel disease, abdominal surgery other than appendectomy or cholecystectomy),
• Occlusive or subocclusive syndrome,
• Digestive perforation or suspicion of perforation,
• Abdominal pain syndrome of undetermined cause,
• Chronic alcohol consumption (>14 units/week),
• Pregnant or parturient or breastfeeding woman or proven absence of contraception,
• Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection/under guardianship or curatorship,
• Person participating in research participating in another trial / having participated in another trial within 2 weeks,
• History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or preventing them from giving informed consent.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Single

Lead Sponsor

University Hospital, RouenOTHER

promotion-ext@chu-caen.fr02-31-06-52-94

chloe.melchior@chu-rouen.fr02 32 88 67 07